Biopharmaceutical company RemeGen Co. Ltd. (9995.HK) (SHA:688331) announced on Tuesday the first patient enrollment in the US for its global phase III clinical trial of telitacicept for generalized myasthenia gravis (gMG).
This milestone advances the global clinical development of telitacicept, offering new hope to gMG patients worldwide. Telitacicept has previously received orphan drug and fast track status from the FDA and breakthrough therapy designation from China's NMPA for myasthenia gravis.
The phase III trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating telitacicept's efficacy and safety in treating gMG. It aims to recruit 180 patients across multiple countries and regions. Myasthenia gravis is a rare autoimmune disease impairing neuromuscular junctions, affecting eye movement, swallowing, speech, general movement, and respiratory function. Current treatments include cholinesterase inhibitors, glucocorticoids, and immunosuppressants, but unmet medical needs persist due to efficacy, tolerability and contraindication issues.
Telitacicept is a dual targeting fusion protein attacking BLyS and APRIL, reducing pathogenic antibody production by targeting B cells and plasma cells. Preliminary studies indicate telitacicept's potential to continuously and effectively improve the clinical status of gMG patients.
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Alvotech launches confirmatory study for Entyvio biosimilar
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in SLE